Expanding its presence in gene therapies, Regeneron has agreed to acquire Decibel Therapeutics for a total equity value of approximately US$109 M at closing, which could rise to approximately US$213 M if contingent value right (CVR) milestones are achieved. Through the deal, Regeneron picks up access to Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss. The proposed transaction builds upon the companies’ existing collaboration signed in 2017 for the development of therapeutics for hearing loss and tinnitus.